Advances in clinical study of curcumin

• Published in: Current pharmaceutical design Vol. 19; no. 11; p. 1966
• Main Authors: Yang, Chunfen, Su, Xun, Liu, Anchang, Zhang, Lin, Yu, Aihua, Xi, Yanwei, Zhai, Guangxi
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01-04-2013
• Subjects: Alzheimer Disease - drug therapy; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - chemistry; Anti-Inflammatory Agents - therapeutic use; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - chemistry; Antineoplastic Agents, Phytogenic - therapeutic use; Cardiovascular Agents - adverse effects; Cardiovascular Agents - chemistry; Cardiovascular Agents - therapeutic use; Clinical Trials as Topic; Curcumin - adverse effects; Curcumin - analogs & derivatives; Curcumin - chemistry; Curcumin - therapeutic use; Gallbladder - drug effects; Humans; Treatment Outcome
• ISSN: 1873-4286
• DOI: 10.2174/138161213805289291

Curcumin has been estimated as a potential agent for many diseases and attracted great attention owing to its various pharmacological activities, including anti-cancer, and anti-inflammatory. Now curcumin is being applied to a number of patients with breast cancer, rheumatoid arthritis, Alzheimer's disease, colorectal cancer, psoriatic, etc. Several clinical trials have stated that curcumin is safe enough and effective. The objective of this article was to summarize the clinical studies of curcumin, and give a reference for future studies.